69138 Federal Register / Vol. 71, No.
229 / Wednesday, November 29, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
MLSCN HTS Assay.
Date: December 14, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Chevy Chase, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Yon Yao, PhD, Scientific
Review Administrator, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6149, MSC 9606,
Bethesda, MD 20892–9606. 301–443–6102.
yyao@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: November 21, 2006.
David Clary,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–9455 Filed 11–28–06; 8:45 am]
BILLING CODE 4140–01–M
jlentini on PROD1PC65 with NOTICES
VerDate Aug<31>2005 16:42 Nov 28, 2006 Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
Public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Cystic Fibrosis
Research and Translation Core Centers (P30).
Date: January 10, 2007.
Time: 8 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard Marriott, 2899 Jefferson
Davis Highway, Arlington, VA 22202.
Contact Person: Dan E. Matsumoto, PhD,
Scientific Review Administrator, Review
Branch, DEA, NIDDK, National Institutes of
Health; Room 749, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452. (301)
594–8894. matsumotod@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: November 21, 2006.
David Clary,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–9456 Filed 11–28–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\29NON1.SGM
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Pathway to independence (PI) Award.
Date: December 11, 2006.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852.
(Telephone Conference Call).
Contact Person: Gerald L. McLaughlin,
PhD, Scientific Review Administrator, Office
of Extramural Affairs, National Institute of
Drug Abuse, NIH, DHHS, Room 220, MSC
8401, 6101 Executive Blvd., Bethesda, MD
20892–8401. 301–402–6626.
gm145a@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 21, 2006.
David Clary,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–9459 Filed 11–28–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
29NON1